Research Article

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary

Table 3

Outcomes and results of CAPTEM.

Primary site, %Pts (n)Prior treatmentCAP/TEM dosage (mg/m2)Results (%)PFS (months)Observed toxicities, %

Peixoto et al. [4]
Pancreatic, 48.3
Small bowel, 20.7
Lung, 10.3
Rectum, 6.9
Appendix, 3.4
Unknown, 10.3
29(i) Octreotide
(ii) Local therapy
(iii) Chemotherapy
(iv) Targeted therapy
Cap: 750
Tem: 200
N/A4.7N/A

Fine et al. [5]
Pancreatic, 39
MEN1, 11
Carcinoids, 22.5
Gastrinoma, 11
Glucagonoma, 5.5
Insulinoma, 11
18(i) Octreotide
(ii) Chemotherapy
(iii) Chemoembolization
Cap: 600
Tem: 150–200
CR: 6
PR: 56
SD: 22
14Thrombocytopenia (grade 3 toxicity), 11
Hand-foot syndrome (grade 2), 5.5
Lymphopenia (grade 1/2), 50
Neutropenia (grade 1/2), 44

Fine et al. [6]
Pancreatic, 39
Atypical/typical carcinoid, 42.8
Pituitary, 10.7
Thyroid gland, 7
28(i) OctreotideCap: 750
Tem: 150–200
CR: 11
PR: 32
SD: 54
PD: 3
22Lymphopenia (grade 3/4), 32
Hyperglycemia (grade 3/4), 15
Thrombocytopenia (grade 3/4), 3

Crespo et al. (abstract only) [7]
Pancreatic, 70.865N/AN/ACR: 3
PR: 45
SD: 42
16Grade 3/4 toxicity, 13.8
Thrombocytopenia, 10.8
Neutropenia, 7.7

Strosberg et al. [8]
Pancreatic, 10030(i) Octreotide
(ii) Local therapy
Cap: 750
Tem: 200
PR: 70
SD: 27
PD: 3
18Grade 3/4 toxicity, 12
Hand-foot syndrome

Ramirez et al. [9]
Pancreatic, 52
Small bowel, 31
Lung, 10
Rectal, 7
29(i) Cytoreduction
(ii) Targeted therapy
(iii) Radionuclide therapy
(iv) Chemotherapy
Cap: 750
Tem: 200
PR: 17
SD: 48
PD: 34
12Thrombocytopenia grade 1 (3), grade 2 (3), grade 3 (1)
Lymphocytopenia grade 1 (3), grade 2 (9), grade 3 (3)
Neutropenia (grade 4), 3
Hand-foot syndrome grade 1 (6), grade 2 (3)

Spada et al. [10]
Pancreatic, 55
GI & unknown, 24
Lung, 21
58(i) Octreotide
(ii) Chemotherapy
Cap: 1,500
Tem: 150–200
PR: 22
SD: 52
PD: 23
13Thrombocytopenia (grade 3/4)

Fine et al. [11]
Metastatic NETs10(i) Octreotide
(ii) Chemotherapy
Cap: 750
Tem: 150–200
CR: 16
PR: 34
SD: 50
NAHand-foot syndrome (grade 3), one case.

Saif et al. [12]
Pancreatic, 1007(i) Octreotide
(ii) Local therapy
(iii) Chemotherapy
Cap: 1,000
Tem: 200
PR: 43
SD: 28
PD: 29
12Thrombocytopenia (grade 3), one case.
Fatigue (grade 3), one case
Neutropenia (grade 1/2)
Hand-foot syndrome (grade 1/2)

Abbasi et al. [13]
Pancreatic
Rectum
Colon
Stomach
21(i) Octreotide
(ii) Chemotherapy
(iii) Local therapy
Cap: 600
Tem: 50–200
PR: 57
SD: 23
PD: 20
17No grade 4 toxicity

Ramirez et al. [14]
Pancreatic, 50
Small bowel, 30
Lung, 13
Rectum, 7
30N/AN/APR: 33
SD: 40
PD: 27
11Cytopenia, 25
Hand-foot syndrome, 35

N/A: not available, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, Cap: capecitabine, and Tem: temozolomide.